2025-12-31 - Analysis Report
Okay, let's break down the information provided for RXRX (Recursion Pharmaceuticals Inc.).

**Report on Recursion Pharmaceuticals Inc. (RXRX)**

**0) Introduction**

This report analyzes the recent performance of Recursion Pharmaceuticals Inc. (RXRX) by comparing its return rate to the S&P 500 (VOO), examining its financial health, stock indicators, analyst ratings, and recent news.

**1) Return Rate Comparison**

*   **RXRX Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.
*   **RXRX Cumulative Return:** -33.45%
*   **S&P 500 (VOO) Cumulative Return:** 44.20%
*   **Divergence:** -76.4 (Current), Range: -76.4 to 84.1, Relative Divergence: 0.0
*   **Analysis:** RXRX has significantly underperformed the S&P 500 over the tracked period. The large negative divergence indicates a substantial difference in returns, and a relative divergence of 0.0 suggests the current divergence is at the lowest point of its historical range.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 22.0% | 81.0% | 26.0% | -0.2 | 5.1 |
| 2022-2024  | 11.0% | 81.0% | -10.0% | 0.1 | 3.5 |
| 2023-2025  | 9.0% | 80.0% | -58.0% | 0.1 | 2.1 |

*   **Analysis:**
    *   **CAGR:** The Compound Annual Growth Rate has decreased from 22% to 9% over the observed periods.
    *   **MDD:** The Maximum Drawdown remains consistently high, indicating substantial risk and volatility.
    *   **Alpha:** The Alpha has declined significantly, suggesting a diminishing ability to generate returns above the market benchmark.
    *   **Beta:** A Beta near zero indicates that RXRX's price movements are nearly uncorrelated with the S&P 500, meaning it moves independently from the market.
    *   **Cap(B):** Market capitalization decreased from $5.1B to $2.1B.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** $4.11
*   **Previous Close:** $4.13
*   **Price Change:** -0.48%
*   **5-day SMA:** $4.25
*   **20-day SMA:** $4.46
*   **60-day SMA:** $4.94

*   **Analysis:** The stock price is below all three moving averages (5-day, 20-day, and 60-day), which typically suggests a downward trend. The negative price change from the previous close reinforces this.

**3) Technical Indicators & Signals**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended) - This is an *incorrect signal.* Given the other indicators, this should not be interpreted as a recommendation.
*   **RSI:** 33.33 (Approaching Oversold) - Suggests the stock *may* be undervalued, but further confirmation is needed.
*   **PPO:** -0.43 (Negative) - Indicates a bearish trend.
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90)" - *Contradictory and potentially misleading* given the other data.
*   **Recent Relative Divergence Change:** -3.3 (Negative Trend)
*   **Expected Return (%):** -569.7% - Highly negative expected return, indicating significant risk.

*   **Analysis:** The RSI indicates the stock might be approaching oversold conditions, but the PPO and negative divergence change suggest a continuing bearish trend. The MRI is contradicted by other data points. The negative expected return is a significant red flag.  The "Very Safe" classification is highly questionable.

**4) Recent News & Significant Events**

*   **[2025-12-29]** Insider Selling, CEO Transition, and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook
*   **[2025-12-29]** RXRX Stock Plummet: Here’s What’s Happening
*   **[2025-12-18]** RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains
*   **[2025-12-17]** Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Clinical Data Readout
*   **[2025-12-14]** Nikko Asset Management Americas Inc. Sells 239,589 Shares of Recursion Pharmaceuticals, Inc.
*   **[2025-12-30]** Why RXRX stock attracts global investors

*   **Analysis:** The news headlines present a mixed picture. While there's a JPMorgan upgrade and interest from global investors, there are also reports of insider selling, a stock plummet, and concerns around CEO transition. The news is net negative.

**4-2) Analyst Opinions**

*   **Consensus:** Hold (Mean: 2.50)
*   **Opinions:** 7 Analysts
*   **Target Price (avg/high/low):** $7.00 / $11.00 / $3.00
*   **Recent Rating Changes:** No changes are indicated

*   **Analysis:** The analyst consensus is "Hold," with a significant spread between the high and low target prices. This suggests uncertainty about the stock's future performance.

**5) Recent Earnings Analysis**

| 날짜       | EPS    | 매출       |
|------------|--------|------------|
| 2025-11-05 | -0.36  | 0.01 B$  |
| 2025-08-05 | -0.41  | 0.02 B$  |
| 2025-05-05 | -0.50  | 0.01 B$  |
| 2024-11-06 | -0.34  | 0.03 B$  |
| 2025-11-05 | -0.34  | 0.03 B$  |

*   **Analysis:** The company is consistently reporting negative Earnings Per Share (EPS). Revenue is fluctuating between $0.01B and $0.03B.

**6) Financial Information**

Revenue and Profitability:

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.00B  | -194.74%      |
| 2025-06-30 | $0.02B  | -5.54%        |
| 2025-03-31 | $0.01B  | -47.31%      |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |

Capital and Profitability:

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-09-30 | $1.05B  | -15.50%  |
| 2025-06-30 | $0.92B  | -18.70%  |
| 2025-03-31 | $0.93B  | -21.68%  |
| 2024-12-31 | $1.03B  | -17.29%  |
| 2024-09-30 | $0.52B  | -18.27%  |

*   **Analysis:** Revenue is inconsistent, and profit margins are generally negative, indicating the company is struggling to generate profit.  The negative Return on Equity (ROE) further highlights profitability concerns. Equity has generally increased over the periods.

**7) Comprehensive Analysis (Summary)**

RXRX has significantly underperformed the S&P 500. Financial indicators show inconsistent revenue, negative profit margins, and negative EPS. Technical indicators suggest a continuing bearish trend, although the RSI indicates the stock may be approaching oversold conditions. Recent news is mixed, with reports of positive catalysts alongside negative events like insider selling. Analyst opinions are neutral ("Hold"), with a wide range of target prices reflecting uncertainty. The MRI (Market Risk Indicator) result is contradictory, given other data and should not be used as an investment recommendation.

**Conclusion:** Based on the available data, RXRX appears to be a high-risk investment. The company's poor financial performance, underperformance compared to the market, and recent news events raise concerns. While the analyst consensus is "Hold," the significant divergence in target prices suggests a high degree of uncertainty.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.